The median (95% CI) DFS of patients with low tumor PLK5 mRNA expression was 31.0 (25.7–36.3) months; the 3-year and 5-year DFS rates were 43.0% and 0.0%, respectively, in NSCLC patients (Table 6). This evidence concerns the gene PLK5 and neoplasm.